Uncategorized Archives - Page 66 of 157

ThursdayMar 17, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…

ThursdayMar 17, 2022 9:00 am

Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program

Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke Companies in diagnostic space posting record revenues, double-digit YOY increases Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programs Competitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, and skin changes Clinical research reveals that volatile blood sugar fluctuations are a primary risk factor for rapidly rising cases of metabolic syndrome - a cluster of diseases that include diabetes, dementia, cardiovascular issues, and stroke. Abbott (NYSE: ABT), a global healthcare company targeting the…

FridayMar 11, 2022 10:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001

Mydecine recently reported a positive Pre-IND meeting with the FDA for the MYCO-001 smoking cessation study According to the Center for Disease Control (“CDC”), tobacco is the leading cause of preventable deaths in the U.S. Following the FDA meeting, the company now intends to perform a Phase 2b study and then a Phase 3 study instead of a seamless Phase 2/3 clinical trial Mydecine plans to submit a request for breakthrough therapy status with its IND submission Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has continually taken steps toward fulfilling its mission to become a trusted source of safe and…

WednesdayMar 09, 2022 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Updates Recent Product Diversification Efforts and Strategic Acquisitions Developments; Announces VP Of Sales & Marketing Appointment

In a recent update, InMed Pharmaceuticals president and CEO, Eric A. Adams, lauded the company’s progress and achievements so far, particularly with its product diversification and strategic acquisitions Adams noted the company’s commitment to launching more products and executing more programs to continue growing its product portfolio InMed also announced the appointment of Gerald (“Jerry”) P. Griffin III as Vice President of Sales and Marketing at BayMedica, its wholly-owned subsidiary In a conference call and webcast on February 15, 2022, Eric A. Adams, President and Chief Executive Officer of InMed Pharmaceuticals (NASDAQ: INM), emphasized the company’s successful product diversification and…

MondayMar 07, 2022 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference

The company also participated in the H.C. Wainwright BioConnect Conference earlier in January CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. During the event, CEO John Climaco provided a corporate presentation and then participated in a…

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

FridayMar 04, 2022 9:30 am

Study Finds That Walkable Neighborhoods Decrease Prevalence of Diabetes, Obesity

A new study has found that individuals living in neighborhoods having access to outdoor activities and parks have a reduced chance of suffering from obesity or diabetes because the neighborhood residents are more active. Data shows that more than 11% of the U.S. population has diabetes with almost one-half of adults also suffering from obesity. Gillian L. Booth, colead author of the study, stated that the built environment influenced the levels of physical activity an individual undertook, through the promotion of active forms of transportation, such as cycling and walking, over passive ones, such as driving a car. The built…

ThursdayMar 03, 2022 9:30 am

Researchers Uncover Why Naked Mole Rats Live Long

A new study has found that naked mole rats demonstrate exceptional resistance to cancer and aging. Naked mole rats have long interested researchers involved in cancer research and aging research. Recently, researchers from the Kumamoto University in Japan succeeded in isolating stem cells from the brains of these rodents. In their report, the researchers explained how these cells helped maintain body homeostasis, which is important in cancer resistance and aging. Cancer and aging is caused by the depletion and dysfunction of tissue-specific stem cells, which are cells that differentiate to form specialized cells. These cells were found throughout the bodies…

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

WednesdayMar 02, 2022 9:30 am

Researchers to Study Why Music, Art Therapy Benefits Mental Health Patients

The National Endowment for the Arts is sponsoring an arts therapy initiative known as Creative Forces in partnership with the Department of Veterans Affairs and Department of Defense. Art therapies are increasingly being used to treat various brain conditions, including Alzheimer’s, Parkinson’s disease, depression and post-traumatic stress disorder. However, most of these therapies, ranging from poetry to music to visual arts, haven’t undergone exhaustive scientific testing. Brain researchers and artists have started an initiative called the NeuroArts Blueprint to conduct research into this. The initiative is the result of collaboration between the Aspen Institute’s Health, Medicine and Society Program, and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001

InMed Pharmaceuticals Inc. (NASDAQ: INM) Updates Recent Product Diversification Efforts and Strategic Acquisitions Developments; Announces VP Of Sales & Marketing Appointment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Study Finds That Walkable Neighborhoods Decrease Prevalence of Diabetes, Obesity

Researchers Uncover Why Naked Mole Rats Live Long

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Researchers to Study Why Music, Art Therapy Benefits Mental Health Patients

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search